T-cell acute lymphoblastic leukemia (Cancer)
Information
- Disease name
- T-cell acute lymphoblastic leukemia
- Disease ID
- DOID:5603
- Description
- "An acute lymphoblastic leukemia that is characterized by too many T-cell lymphoblasts found in the bone marrow and blood." [url:https\://www.cancer.gov/publications/dictionaries/cancer-terms/expand/T]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| NOTCH1 | 9 | 136,494,433 | 136,546,048 | 4 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04984356 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL | January 14, 2022 | August 2026 |
| NCT02518113 | Completed | Phase 1/Phase 2 | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL | October 1, 2015 | January 15, 2018 |
| NCT01950286 | Completed | Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. | October 2002 | ||
| NCT05509855 | Enrolling by invitation | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | August 22, 2022 | July 1, 2037 | |
| NCT06420076 | Not yet recruiting | Phase 1/Phase 2 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells | September 10, 2024 | December 28, 2026 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT05995028 | Recruiting | Phase 1 | Universal 4SCAR7U Targeting CD7-positive Malignancies | October 31, 2023 | December 31, 2026 |
| NCT06316427 | Recruiting | Phase 1/Phase 2 | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma | March 22, 2024 | March 30, 2028 |
| NCT03081910 | Recruiting | Phase 1 | Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen | November 1, 2017 | September 1, 2040 |
| NCT05032599 | Recruiting | Phase 1 | Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | September 14, 2021 | September 1, 2024 |
| NCT05277753 | Recruiting | Phase 1 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | March 15, 2022 | December 31, 2025 |
| NCT05289687 | Recruiting | Phase 2 | Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL | May 25, 2023 | October 31, 2024 |
| NCT05290155 | Recruiting | Phase 1 | Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies | May 4, 2022 | November 1, 2024 |
| NCT05376111 | Recruiting | Phase 2 | Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients | April 1, 2022 | May 1, 2024 |
| NCT04972942 | Recruiting | Phase 1 | Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma | May 22, 2023 | September 2028 |
| NCT05596266 | Recruiting | Phase 1 | CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia | October 25, 2022 | October 25, 2025 |
| NCT05679895 | Recruiting | Phase 1 | Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL | January 31, 2023 | January 25, 2026 |
| NCT05832125 | Recruiting | Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia | December 14, 2021 | March 2024 | |
| NCT04934774 | Unknown status | Phase 1 | Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances | December 1, 2020 | June 1, 2023 |
| NCT04594135 | Unknown status | Phase 1 | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies | December 1, 2020 | November 30, 2023 |
| NCT04033302 | Unknown status | Phase 1/Phase 2 | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | September 1, 2019 | December 31, 2023 |
| NCT04860817 | Withdrawn | Early Phase 1 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | December 1, 2021 | November 1, 2023 |
- Disase is a (Disease Ontology)
- DOID:9952
- Cross Reference ID (Disease Ontology)
- ICDO:9729/3
- Cross Reference ID (Disease Ontology)
- ICDO:9837/3
- Cross Reference ID (Disease Ontology)
- MESH:D015458
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023492
- Exact Synonym (Disease Ontology)
- acute T cell leukemia
- Exact Synonym (Disease Ontology)
- Precursor T Lymphoblastic Leukemia
- Exact Synonym (Disease Ontology)
- precursor T-lymphoblastic lymphoma/leukemia
- Exact Synonym (Disease Ontology)
- T Acute Lymphoblastic Leukemia
- Exact Synonym (Disease Ontology)
- T-cell acute lymphocytic leukaemia
- Exact Synonym (Disease Ontology)
- T-cell leukemia
- Exact Synonym (Disease Ontology)
- T-cell lymphoblastic leukemia/lymphoma